Signature Equity Partners’s BioNTech BNTX Stock Holding History

Signature Equity Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	-$267	–	1588
2026 Q1	$267	Hold	3	–	–	﹤0.01%	1446
2025 Q4	$286	Buy	+3	New	+$302	﹤0.01%	1600

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Signature Equity Partners's BNTX Position: Q2 2026 in Review

Signature Equity Partners sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 3 shares — an estimated $267 sold.

Signature Equity Partners first reported a position in BNTX in Q4 2025 and held it in 2 quarters. The position peaked at $286 in Q4 2025. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Signature Equity Partners reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Signature Equity Partners sold 3 BioNTech shares in Q2 2026, an estimated $267.
Signature Equity Partners first reported a position in BioNTech in Q4 2025 and held it in 2 quarters.
Signature Equity Partners's BioNTech position peaked at $286 in Q4 2025.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.